Amneal Pharmaceuticals Inc (NASDAQ: AMRX) is 4.92% higher on its value in year-to-date trading and has touched a low of $5.01 and a high of $9.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AMRX stock was last observed hovering at around $8.22 in the last trading session, with the day’s gains setting it 0.09%.
Currently trading at $8.31, the stock is 5.39% and 1.07% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.45 million and changing 1.09% at the moment leaves the stock 10.02% off its SMA200. AMRX registered 55.33% gain for a year compared to 6-month gain of 11.84%. The firm has a 50-day simple moving average (SMA 50) of $8.226 and a 200-day simple moving average (SMA200) of $7.5419.
The stock witnessed a 6.13% loss in the last 1 month and extending the period to 3 months gives it a -5.68%, and is 3.10% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.35% over the week and 3.36% over the month.
Amneal Pharmaceuticals Inc (AMRX) has around 7850 employees, a market worth around $2.57B and $2.68B in sales. Fwd P/E is 11.38. Profit margin for the company is -6.88%. Distance from 52-week low is 65.87% and -12.30% from its 52-week high. The company has generated returns on investments over the last 12 months (-8.50%).
with sales reaching $708.47M over the same period.The EPS is expected to shrink by -3.91% this year, but quarterly earnings will post 15.80% year-over-year. Quarterly sales are estimated to grow 14.83% in year-over-year returns.
257.0 institutions hold shares in Amneal Pharmaceuticals Inc (AMRX), with institutional investors hold 97.09% of the company’s shares. The shares outstanding are 309.77M, and float is at 126.78M with Short Float at 2.60%. Institutions hold 46.44% of the Float.
The top institutional shareholder in the company is UBS GROUP AG with over 21.85 million shares valued at $138.74 million. The investor’s holdings represent 7.1106 of the AMRX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.99 million shares valued at $88.86 million to account for 4.5542 of the shares outstanding. The other top investors are TPG GP A, LLC which holds 12.33 million shares representing 4.0122 and valued at over $78.29 million, while BLACKROCK INC. holds 3.6717 of the shares totaling 11.28 million with a market value of $71.64 million.
Amneal Pharmaceuticals Inc (AMRX) Insider Activity
The most recent transaction is an insider sale by Patel Gautam, the company’s Director. SEC filings show that Patel Gautam sold 62,590 shares of the company’s common stock on Jan 08 ’25 at a price of $8.01 per share for a total of $0.5 million. Following the sale, the insider now owns 1.97 million shares.
Amneal Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 02 ’25 that Patel Gautam (Director) sold a total of 17,410 shares of the company’s common stock. The trade occurred on Jan 02 ’25 and was made at $8.01 per share for $0.14 million. Following the transaction, the insider now directly holds 2.03 million shares of the AMRX stock.
Still, SEC filings show that on Jan 02 ’25, Gautam J Patel (Director) Proposed Sale 320,000 shares at an average price of $8.00 for $2.56 million. The insider now directly holds shares of Amneal Pharmaceuticals Inc (AMRX).
